Replies to post #114903 on NorthWest Biotherapeutics Inc (NWBO)

[chinatown1980]

No you are wrong. In his article on Feb 27th Smith said "This is truly an asymmetric investment opportunity as the upside in the chance of success could produce a $750 million to $1.5 billion market valuation based on looking at the market capitalizations of companies with successful phase 3 trials of cancer drugs addressing comparable cancer opportunities."

Now please run your calcs again based on that market cap. Also, go ahead and use 500,000,000 as the OS as I think that will be closer to reality at that time. Would your cost basis still be in the red? I suspect so, as would all long time shareholders. Yay us! That's best case scenario!

[flipper44]

Correction: Larry's site does not make clear whom is responding to who in the comment section. It was Boshie (not Larry) that made this statement. You kind of have to tinker with the highlighting to figure it out.

No doubt the last financing hurt the company and any shareholders, in terms of dilution, however, I believe that with positive results, the market cap of NWBO could be much higher than KITE or JUNO (which have been in the 2 – 4 Billion range), as they are still in phase 2 trials. With positive results, there will be some emotional over shoot (enhanced by shorts as well), but I could see the stock jumping at least to $20 – $30 a share and up to $80 (~20 Billion Market Cap), as NWBO is positioned to generate revenue immediately with their partnership with Cognate, albeit not ramped up, but enough to get things started. Moreover, a successful P3 also sheds light on DCVax Direct, which could have multibillion dollar implications. Boshie

Sorry Larry, I'm far more in line with Boshie regarding PPS.

[Pablosrv]

I like all those prices. I hope God hears you.